32 related articles for article (PubMed ID: 26456281)
1. Longitudinal Transcription Profiling of Bladder Cancers Dictate the Response to BCG Treatment and Disease Progression.
Lee SY; Lee YH; Kim TM; Ha US
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203315
[TBL] [Abstract][Full Text] [Related]
2. Bacillus Calmette-Guérin-induced lupus vulgaris in a patient with Mendelian susceptibility to mycobacterial disease caused by a novel STAT1 variation.
Shionoya A; Yoto Y; Hida T; Ishikawa A; Hasegawa T; Tsugawa T; Uhara H
Br J Dermatol; 2023 Jan; 188(1):142-143. PubMed ID: 36689501
[No Abstract] [Full Text] [Related]
3. The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin.
Gontero P; Sylvester R; Pisano F; Joniau S; Oderda M; Serretta V; Larré S; Di Stasi S; Van Rhijn B; Witjes AJ; Grotenhuis AJ; Colombo R; Briganti A; Babjuk M; Soukup V; Malmström PU; Irani J; Malats N; Baniel J; Mano R; Cai T; Cha EK; Ardelt P; Vakarakis J; Bartoletti R; Dalbagni G; Shariat SF; Xylinas E; Karnes RJ; Palou J
BJU Int; 2016 Jul; 118(1):44-52. PubMed ID: 26469362
[TBL] [Abstract][Full Text] [Related]
4. γ Irradiated Mycobacteria Enhance Survival in Bladder Tumor Bearing Mice Although Less Efficaciously than Live Mycobacteria.
Noguera-Ortega E; Rabanal RM; Secanella-Fandos S; Torrents E; Luquin M; Julián E
J Urol; 2016 Jan; 195(1):198-205. PubMed ID: 26165584
[TBL] [Abstract][Full Text] [Related]
5. Killed but metabolically active Mycobacterium bovis bacillus Calmette-Guérin retains the antitumor ability of live bacillus Calmette-Guérin.
Secanella-Fandos S; Noguera-Ortega E; Olivares F; Luquin M; Julián E
J Urol; 2014 May; 191(5):1422-8. PubMed ID: 24333111
[TBL] [Abstract][Full Text] [Related]
6. Bacillus Calmette-Guérin (BCG) unresponsive non-muscle-invasive bladder cancer: are the subgroups equal?
Tan WS; Grajales V; Bree K; Li R; Nogueras-Gonzalez GM; Navai N; Dinney C; Kamat AM
BJU Int; 2023 Oct; 132(4):384-386. PubMed ID: 37246493
[No Abstract] [Full Text] [Related]
7. Sequential Chemotherapy with Gemcitabine and Docetaxel: Breaking the Chains of bacillus Calmette-Guérin.
Meeks JJ; Sexton WJ; Clark PE
J Urol; 2022 Sep; 208(3):526-527. PubMed ID: 35549526
[No Abstract] [Full Text] [Related]
8. Prognostic significance of Bacillus Calmette-Guérin failure classification in non-muscle-invasive bladder cancer.
Singh BP; Dhakad U
BJU Int; 2012 Sep; 110(6):E163-4. PubMed ID: 22925707
[No Abstract] [Full Text] [Related]
9. Getting the Most Out of bacillus Calmette-Guérin for Treatment of Bladder Cancer.
Lamm DL
J Urol; 2016 Jan; 195(1):7-8. PubMed ID: 26456281
[No Abstract] [Full Text] [Related]
10. Modulating the immune response to Bacillus Calmette-Guérin (BCG): a novel way to increase the immunotherapeutic effect of BCG for treatment of bladder cancer?
Sapre N; Corcoran NM
BJU Int; 2013 Oct; 112(6):852-3. PubMed ID: 24028766
[No Abstract] [Full Text] [Related]
11. [The bacillus Calmette-Guérin as immunomodulator in bladder cancer].
Vázquez-Lavista LG; Flores-Balcázar CH; Llorente L
Rev Invest Clin; 2007; 59(2):146-52. PubMed ID: 17633803
[TBL] [Abstract][Full Text] [Related]
12. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
Turker P; Turkeri L
Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
